WallStreetZenWallStreetZen

NASDAQ: INM
Inmed Pharmaceuticals Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

INM past revenue growth

How has INM's revenue growth performed historically?
Company
239.77%
Industry
151.46%
Market
17.61%
INM's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
INM's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
INM's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

INM earnings and revenue history

Current Revenue
$5.5M
Current Earnings
-$6.4M
Current Profit Margin
-115.8%

INM Return on Equity

Current Company
-54.3%
Current Industry
-63.5%
Current Market
188%
INM's Return on Equity (-54.3%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when INM announces earnings.

INM Return on Assets

Current Company
-46.2%
Current Industry
2.9%
INM is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

INM Return on Capital Employed

Current Company
-46.76%
Current Industry
19.5%
INM has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

INM vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
INM$5.49M-$5.75M-$6.35M+354.96%N/A
GLMD$0.00-$7.46M-$6.91M-100.00%N/A
QLGN$0.00-$11.89M-$13.42M-100.00%N/A
SCNI$0.00N/A-$10.95MN/AN/A
GRI$0.00-$10.95M-$13.04M-100.00%N/A
View Top Biotech Stocks

INM earnings dates

Next earnings date
May 13, 2024

Inmed Pharmaceuticals Earnings & Revenue FAQ

What were INM's earnings last quarter?

On Invalid Date, Inmed Pharmaceuticals (NASDAQ: INM) reported Q4 2023 earnings per share (EPS) of -$0.19, up 79.12% year over year. Total Inmed Pharmaceuticals earnings for the quarter were -$1.48 million. In the same quarter last year, Inmed Pharmaceuticals's earnings per share (EPS) was -$0.91.

If you're new to stock investing, here's how to buy Inmed Pharmaceuticals stock.

What was INM's earnings growth in the past year?

As of Q2 2024, Inmed Pharmaceuticals's earnings has grown year over year. Inmed Pharmaceuticals's earnings in the past year totalled -$6.35 million.

What is INM's earnings date?

Inmed Pharmaceuticals's earnings date is Invalid Date. Add INM to your watchlist to be reminded of INM's next earnings announcement.

What was INM's revenue last quarter?

On Invalid Date, Inmed Pharmaceuticals (NASDAQ: INM) reported Q4 2023 revenue of $1.24 million up 163.99% year over year. In the same quarter last year, Inmed Pharmaceuticals's revenue was $469.78 thousand.

What was INM's revenue growth in the past year?

As of Q2 2024, Inmed Pharmaceuticals's revenue has grown 239.77% year over year. This is 88.32 percentage points higher than the US Biotechnology industry revenue growth rate of 151.46%. Inmed Pharmaceuticals's revenue in the past year totalled $5.49 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.